Allogene Therapeutics Inc (ALLO)
2.11
+0.06
(+2.93%)
USD |
NASDAQ |
Nov 21, 16:00
2.11
0.00 (0.00%)
After-Hours: 20:00
Allogene Therapeutics Enterprise Value: 150.84M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 150.84M |
| November 20, 2024 | 138.26M |
| November 19, 2024 | 152.94M |
| November 18, 2024 | 159.23M |
| November 15, 2024 | 184.39M |
| November 14, 2024 | 224.23M |
| November 13, 2024 | 278.74M |
| November 12, 2024 | 303.90M |
| November 11, 2024 | 356.32M |
| November 08, 2024 | 354.23M |
| November 07, 2024 | 377.29M |
| November 06, 2024 | 383.58M |
| November 05, 2024 | 335.36M |
| November 04, 2024 | 337.45M |
| November 01, 2024 | 278.74M |
| October 31, 2024 | 243.71M |
| October 30, 2024 | 261.52M |
| October 29, 2024 | 295.04M |
| October 28, 2024 | 269.90M |
| October 25, 2024 | 219.62M |
| October 24, 2024 | 240.57M |
| October 23, 2024 | 288.75M |
| October 22, 2024 | 295.04M |
| October 21, 2024 | 295.04M |
| October 18, 2024 | 303.42M |
| Date | Value |
|---|---|
| October 17, 2024 | 271.99M |
| October 16, 2024 | 305.51M |
| October 15, 2024 | 276.18M |
| October 14, 2024 | 259.42M |
| October 11, 2024 | 263.61M |
| October 10, 2024 | 257.33M |
| October 09, 2024 | 261.52M |
| October 08, 2024 | 282.47M |
| October 07, 2024 | 248.95M |
| October 04, 2024 | 274.09M |
| October 03, 2024 | 255.23M |
| October 02, 2024 | 238.47M |
| October 01, 2024 | 267.80M |
| September 30, 2024 | 295.04M |
| September 27, 2024 | 163.89M |
| September 26, 2024 | 124.16M |
| September 25, 2024 | 103.24M |
| September 24, 2024 | 113.70M |
| September 23, 2024 | 113.70M |
| September 20, 2024 | 140.88M |
| September 19, 2024 | 163.89M |
| September 18, 2024 | 157.61M |
| September 17, 2024 | 157.61M |
| September 16, 2024 | 132.52M |
| September 13, 2024 | 174.34M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-81.83M
Minimum
Nov 29 2023
6.280B
Maximum
May 22 2020
1.687B
Average
1.044B
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals Inc | 1.671B |
| AIM ImmunoTech Inc | 9.017M |
| Perspective Therapeutics Inc | -63.40M |
| Protalix BioTherapeutics Inc | 94.82M |
| Armata Pharmaceuticals Inc | 166.25M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -66.29M |
| Total Expenses (Quarterly) | 61.05M |
| EPS Diluted (Quarterly) | -0.32 |
| Earnings Yield | -73.93% |
| Normalized Earnings Yield | -81.58 |